Get my own profile
Public access
View all12 articles
2 articles
available
not available
Based on funding mandates
Co-authors
- Philippe BeutelsProfessor at Vaccine & Infectious Disease Institute, University of Antwerp, BelgiumVerified email at uantwerpen.be
- Lander WillemUniversity of AntwerpVerified email at uantwerpen.be
- Niel HensProfessor of BiostatisticsVerified email at uhasselt.be
- Roselinde KesselsMaastricht UniversityVerified email at maastrichtuniversity.nl
- Elise KuylenAssociate Director, Value Evidence Neisseria, GlaxoSmithKlineVerified email at gsk.com
- Joke BilckeCenter for Health Economics Research and Modeling of Infectious Diseases, University of AntwerpVerified email at uantwerp.be
- Jacco WallingaLeiden University Medical Center; RIVMVerified email at rivm.nl
- Wim DelvaSACEMA and Dept of Global Health (Stellenbosch Univ) and WimmyVerified email at sun.ac.za
- Albert Jan van HoekHealth economist / Infectious disease modeller, RIVMVerified email at rivm.nl
- G. Ardine de WitUniversity Medical Centre Utrecht & National Institute of Public Health, the NetherlandsVerified email at rivm.nl
Follow
Frederik Verelst
Director, Vaccines Value Evidence / Health Outcomes, GlaxoSmithKline
Verified email at gsk.com